Overview

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Mineralocorticoid Receptor Antagonists